Pathways to Better Outcomes in Systemic Lupus Erythematosus
Translating Pathophysiology into Targeted Treatments
Insights Into Pathogenic Mechanisms in SLE
American College of Rheumatology (ACR) Annual Meeting Abstracts.
October 19th-24th, 2018. Chicago, Illinios.
Personalized immunomonitoring uncovers molecular networks that stratify lupus patients.
Banchereau R, et al. Cell. 2016;165(3):551-565.
Diagnostic criteria for systemic lupus erythematosus: has the time come?
Bertsias GK, et al. Nat Rev Rheumatol. 2013;9(11):687-694.
Advances in understanding the role of type I interferons in systemic lupus erythematosus.
Crow MK. Curr Opin Rheumatol. 2014;26(5):467-474.
Definition and initial validation of a Lupus Low Disease Activity State (LLDAS).
Franklyn K, et al. Ann Rheum Dis. 2016;75(9):1615-1621.
Anifrolumab, an anti-interferon-α receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus.
Furie R, et al. Arthritis Rheumatol. 2017;69(2):376-386.
A phase 3, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits BLyS [B lymphocyte stimulator], in patients with systemic lupus erythematosus.
Furie R, et al. Arthritis Rheum. 2011;63(12):3918-3930.
The effect of ethnicity and genetic ancestry on the epidemiology, clinical features and outcome of systemic lupus erythematosus.
Lewis MJ, Jawad AS. Rheumatology (Oxford).
Efficacy and safety of atacicept in patients with systemic lupus erythematosus: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled, parallel-arm, phase IIb study.
Merrill JT, et al. Arthritis Rheumatol. 2018;70(2):266-276.
Connective tissue diseases: remission in SLE—are we there yet?
Morand EF. Nat Rev Rheumatol. 2016;12(12):696-698.
Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hoc analysis of the phase IIb MUSE trial of anifrolumab.
Morand EF, et al. Ann Rheum Dis. 2018;77(5):706-713.
Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.
Navarra SV, et al. Lancet. 2011;377(9767):721-731.
Treat-to-target in systemic lupus erythematosus: recommendations from an international task force.
van Vollenhoven RF, et al. Ann Rheum Dis. 2014;73(6):958-967.
Comparison of remission and Lupus Low Disease Activity State in damage prevention in a United States systemic lupus erythematosus cohort.
Petri M, Magder LS. Arthritis Rheumatol. May 2018. [Epub ahead of print].
Lupuzor/P140 peptide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled phase IIb clinical trial.
Zimmer R, et al. Ann Rheum Dis. 2013;72(11):1830-1835.
Classification Criteria
1997 Update of the 1982 American College of Rheumatology revised criteria for classification of systemic lupus erythematosus
Hochberg MC. Arthritis Rheum. 1997;40(9):1725.
Derivation and validation of Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus
Petri M, et al. Arthritis Rheum. 2012;64(8):2677-2686.
Patient Resources
American College of Rheumatology
Lupus Foundation of America
Lupus Research Alliance
Disease Activity Indices
A pilot study to determine the optimal timing of the Physician Global Assessment (PGA) in patients with systemic lupus erythematosus.
Aranow C. Immunol Res. 2015;63(1-3):167-169.
Novel evidence-based Systemic Lupus Erythematosus Responder Index
Furie RA, et al. Arthritis Rheum. 2009;61(9):1143-1151.
BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus.
Isenberg DA, et al. Rheumatology (Oxford). 2005;44(7):902-906.
Combined oral contraceptives in women with systemic lupus erythematosus.
Petri M, et al. N Engl J Med. 2005;353(24):2550-2558.
Development and initial validation of the Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index 50.
Touma Z, et al. J Rheumatol. 2011;38(2):275-284.
Pathways to Better Outcomes in Systemic Lupus Erythematosus
Translating Pathophysiology into Targeted Treatments
| Faculty: | Richard A. Furie, MD; Eric Morand, MBBS (Hons), FRACP, PhD; Virginia Pascual, MD |
| Release: | 01/07/2019 |
| Expiration: | 01/07/2020 |
